Associate
Candace represents pharmaceutical patent holders in ANDA litigations arising under the Hatch-Waxman Act. Her litigation experience covers various aspects of trial preparation, including discovery and pre-trial activities. Candace also drafts and prosecutes patent applications, assists in client counseling, and prepares infringement and freedom to operate opinions in a wide range of chemical-related technology areas.
While in law school, Candace worked as a summer associate and law clerk at Finnegan, assisting in litigation matters before federal district courts and with prosecuting patent applications and client counseling. She also worked as a research assistant, conducting research on international and comparative patent law and assisting in the preparation of a study for the United Nations Convention on Biological Diversity. Candace also completed the TI:GER certificate program, where she advised a biomedical engineering Ph.D. student on intellectual property matters, including patentability, freedom-to-operate, and obtaining protection for and commercializing their technology.
During her undergraduate studies, Candace worked in a microbiology and biochemistry lab, where her research focused on synthetic biology and protein engineering in the fields of infectious diseases and drug discovery.
Candace is committed to her pro bono practice and represents honorably discharged veterans before the U.S. Court of Appeals for Veterans Claims.
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
1:21-cv-00870, D. Del., Judge Hall
Articles
Southeast Litigation Update: May 2023 Southeast Litigation Update: May 2023
August 17, 2023
At the PTAB Blog
PGR Petition Inadvertently Served on Incorrect Party Was Entitled to Original Filing Date and Not Time-Barred PGR Petition Inadvertently Served on Incorrect Party Was Entitled to Original Filing Date and Not Time-Barred
June 7, 2023
Prosecution First Blog
Punctuation Pitfalls: Commas and Periods Kill Patents Punctuation Pitfalls: Commas and Periods Kill Patents
July 22, 2021
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.